Parietal Epithelial Cells Participate in the Formation of Sclerotic Lesions in Focal Segmental Glomerulosclerosis

Bart Smeets,*† Christoph Kuppe,* Eva-Maria Sicking,* Astrid Fuss,* Peggy Jirak,* Toin H. van Kuppevelt,‡ Karlhans Endlich,§ Jack F.M. Wetzels,¶ Hermann-Josef Grüne,§ Jürgen Floege,* and Marcus J. Moeller*

*Division of Nephrology and Immunology, University Hospital of the Aachen University of Technology (RWTH), Aachen, Germany; Departments of †Pathology, ‡Biochemistry, and §Nephrology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands; †Department of Anatomy and Cell Biology, Ernst Moritz Arndt University, Greifswald, Germany; and ¶Department of Cellular and Molecular Pathology, German Cancer Research Centre (DKFZ), Heidelberg, Germany

ABSTRACT

The pathogenesis of the development of sclerotic lesions in focal segmental glomerulosclerosis (FSGS) remains unknown. Here, we selectively tagged podocytes or parietal epithelial cells (PECs) to determine whether PECs contribute to sclerosis. In three distinct models of FSGS (5/6-nephrectomy + DOCA-salt; the murine transgenic chronic Thy1.1 model; or the MWF rat) and in human biopsies, the primary injury to induce FSGS associated with focal activation of PECs and the formation of cellular adhesions to the capillary tuft. From this entry site, activated PECs invaded the affected segment of the glomerular tuft and deposited extracellular matrix. Within the affected segment, podocytes were lost and mesangial sclerosis developed within the endocapillary compartment. In conclusion, these results demonstrate that PECs contribute to the development and progression of the sclerotic lesions that define FSGS, but this pathogenesis may be relevant to all etiologies of glomerulosclerosis.


Focal segmental glomerulosclerosis (FSGS) is one of the most common glomerular pathologies. It was first described in 1925 by Fahr.1 The diagnosis of FSGS relies on histopathologic findings characterized by the presence of adhesions between the glomerular tuft and Bowman’s capsule (BC), focal and segmental lesions with mesangial sclerosis, and obliteration of glomerular capillaries with hyalinosis.2 FSGS is considered primary or idiopathic when no etiology can be identified. Secondary FSGS is associated with infections, obesity, chronic hypertension, immunologic processes (e.g., IgA nephropathy and immune complex nephritis), and drug abuse. Up to 18% of primary FSGS cases are attributed to genetic mutations.3

FSGS is not a specific disease entity, but rather a pattern of specific histologic changes with quite diverse clinical behavior. Recently, various morphologic variants have been defined and a classification has been proposed to better address the diversity.4 Five light microscopic variants of FSGS were defined: the perihilar variant (lesions...
predominantly located at the vascular pole), the tip variant (for lesions located at the urinary pole), the cellular variant (characterized by endocapillary hypercellularity), the collapsing variant (collapse of the glomerular tuft associated with epithelial cell hypertrophy and hyperplasia), and finally, FSGS not otherwise specified (NOS) or classic FSGS, if lesions do not fit into one of the above mentioned categories. All morphologic variants are accompanied by some degree of epithelial hyperplasia, being less prominent in the perihilar variant and sometimes very prominent in the cellular and collapsing variant. It is still unclear whether the morphologic appearance of the glomerular lesions is associated with a specific cause or pathomechanism or the degree or developmental stage of the disease.

It is now generally accepted that loss of podocytes beyond a certain threshold triggers glomerulosclerosis. In addition, almost any glomerular disease, which ultimately leads to end-stage renal failure, triggers the formation of FSGS lesions. For this reason, FSGS has been called "the final common pathway" in the development of end-stage renal disease.

So far, the pathogenesis of a segmental glomerular lesion defining FSGS is not completely resolved. Understanding the sequence of events resulting in a sclerotic lesion is an important prerequisite for the development of specific therapeutic approaches. Great advances have been made in seminal studies of Kriz and co-workers. In these studies, it was shown that the classic FSGS lesion was associated with the formation of adhesions (synechia) between BC and the glomerular tuft. Nonetheless, it is still unclear how an adhesion progresses toward a segmental or even global sclerotic lesion of the glomerulus. In previous studies, it has been suggested that parietal epithelial cells (PECs) can proliferate to form cellular glomerular lesions observed in crescentic glomerulonephritis and collapsing glomerulopathy. Le Hir and Kriz proposed that cellular adhesions were formed predominantly by injured podocytes. In this study, we employed a transgenic approach and cell lineage tracing experiments to determine whether PECs are involved in the formation of glomerular sclerotic lesions in models with different underlying etiologies. For this purpose, podocytes and PECs were specifically traced in models of FSGS induced by maladaptation to chronic hypertension, or by a primary injury to the podocytes. The findings were validated in human biopsies diagnosed with FSGS or nephrosclerosis.

**RESULTS**

**Induction of the 5/6 Nephrectomy + Deoxycorticosterone Acetate–Salt Model for FSGS in Triple Transgenic Mouse Lines**

The 5/6 nephrectomy (Nx) + deoxycorticosterone acetate–salt (DOCA-salt) model was induced in transgenic male mice after podocytes or PECs had been irreversibly labeled by administration of doxycycline (dox) (Figure 1). Proteinuria, as measured by dipstick on spot urine samples, occurred 2 to 4 weeks after implantation of the DOCA pellets. After 12 weeks, histology revealed typical sclerotic lesions in 20 to 50% of all glomeruli. The histopathology of the 5/6 Nx + DOCA-salt model showed a focal and segmental sclerosis of the glomeruli characterized by formation of adhesions between the Bowman’s capsule and the glomerular convolute and obliteration of the capillaries due to hyalinosis and extracellular matrix accumulation in a segment of the glomerular convolute (Figure 1, B through F). Sclerotic lesions and adhesions were seen along the entire periphery of the glomerulus.
from the vascular stalk to the glomerular urinary pole. The phenotype of the glomerulosclerotic lesions was heterogenous in this model, and next to the glomerular sclerotic lesions as described above, which were the most prevalent, the kidneys also showed more “active glomerulosclerosis,” which describe lesions with scarring and/or hyalinosis but also a marked hypertrophy and/or hyperplasia of the glomerular epithelium which lead to the formation of pseudocrescents. Representative examples of active lesions are shown in Figure 1. In summary, focal and segmental lesions were successfully induced in all our transgenic mouse lines required to tag podocytes or PECs.

**Tracing Podocytes in the 5/6 Nx + DOCA-Salt Model for FSGS**

First, podocytes were irreversibly genetically tagged in triple transgenic Pod-rtTA/LC1/R26R mice (Figure 2, A and B). Usage of a dox-inducible labeling system assured that no additional direct genetic labeling occurred during the disease models.\(^{17}\) As shown in Figure 2, C and D, genetically labeled podocytes were absent from sclerotic lesions of affected glomeruli. Stainings for \(\beta\)-galactosidase (\(i.e.,\) the genetic tag of podocytes) and the podocyte marker protein synaptopodin on serial sections confirmed that sclerotic lesions were devoid of podocytes (Figure 2, E\(_1\) through F\(_2\), asterisk). Because in studies so far the genetic label of podocytes still preserved within the unaffected portion of the same glomerulus (arrows, X-gal/H\(_{9252}\)-gal staining is absent from segmental sclerotic lesions (asterisks) but present on Bowman's capsule and covered large segments of the glomerular tuft (Figure 3, M through O). As shown in Figure 3M, CD44 was expressed by a subpopulation of cells in close association with an adhesion between the glomerular tuft and BC (black arrowheads). PECs along other parts of BC were mostly negative for CD44. Morphologic changes of some PECs were interpreted as signs of activation (\(i.e.,\) increased cellular volume, increased density of cells, and thickened BC), mostly close to

![Figure 2](image-url)
Figure 3. Parietal cells contribute to glomerulosclerotic lesions in the 5/6 Nx + DOCA-salt model. (A) Schematic of inducible irreversible genetic tagging of PECs. (B) Normal β-gal staining of genetically labeled PECs (blue, arrow). Note that, after 5/6 Nx + DOCA-salt treatment, weak nonspecific β-gal staining can also be observed along the tissue interfaces within the glomerular tuft (arrow with tails), which is not present directly after genetic labeling. (C through J) Representative examples of glomeruli affected by segmental or global sclerotic lesions. (C) Small segmental lesion showing bridging and migration of β-gal–positive PECs in the involved tuft segment (arrowhead). Note that single tubular cells can also be labeled in this mouse (arrow). (D and E) Serial sections show a β-gal–positive cellular adhesion (white arrowhead) from where β-gal–positive cells invade a segment of the glomerular tuft (arrowheads; arrows, labeled PECs). (F) A cellular lesion (arrowhead) consisting of labeled PECs (arrows) associated with segmental sclerosis (asterisks). (G through I) Late stages with global sclerosis of the glomerular tuft. β-gal–positive PECs cover a large part, or the entire surface, of the tuft (arrowheads; J through K) X-gal/eosin stained cryosections). The arrows mark the genetically labeled PECs on BC. (J through L) Corresponding later stages of largely sclerosed glomeruli are shown on PAS-stained paraffin sections (asterisks). Bowman’s space as well as the glomerular tuft is populated by multiple, often polygonal, cells (arrowheads). Fewer cells can be found in very late stages of globally sclerosed glomeruli (panel (L), on the right). (M) Activated PECs participate in the formation of the sclerotic lesion. Parietal cells express the activation marker CD44 (brown staining) only at the site or in close proximity of the adhesion to BC (black arrowheads) but not at other sites (white arrowhead). A thickened basement membrane of BC also indicates PEC activation. CD44–positive cells invade the glomerular tuft using the adhesion as entry site (arrow). (N) Parietal cells express higher levels of CD44 close to the sclerotic lesion at the vascular stalk (black arrowheads). (O) Example of a glomerulus showing global sclerosis. The glomerular tuft is surrounded by CD44–positive presumptive parietal cells (arrowheads; (A through O) 5/6 Nx + DOCA-salt model of the mouse; (M through O) CD44 immunohistologic staining (brown) costained with PAS).
cellular adhesions (white arrowheads). Not all of these PECs were positive for CD44, suggesting that it is a late marker for activation.

Activated Parietal Cells Deposit Extracellular Matrix
To test whether activated PECs participate in the formation of sclerotic lesions, a costaining with the single-chain antibody LKIV69 and CD44 was performed. The LKIV69 antibody recognizes specifically the extracellular matrix of BC (i.e., specific heparan sulfate moieties) but not of the glomerular tuft.20 Bowman’s capsule type matrix (BC matrix) was detected as thin deposits on the glomerular tuft in early segmental sclerotic lesions (Figure 4A). BC-type matrix was always found in association with CD44-positive PECs. Advanced sclerotic lesions contained more BC-type matrix deposits on the glomerular tuft (Figure 4, B through D). In glomeruli with global sclerosis, the capillary tuft was surrounded by CD44-positive cells and contained BC-type matrix along its entire circumference (Figure 4D). Again, there was colocalization of CD44-positive cells and BC-type matrix. To analyze the microanatomical relationship between the BC-type matrix and the GBM, both types of matrixes were selectively stained (Figure 5). Within small lesions (Figure 5, A and B), BC-type matrix is deposited along the outer surface of the GBM, which remains preserved also within the lesion. Note that BC-type matrix is not always present at the site of the adhesion (Figure 5B, white arrow), indicating that early adhesions may be purely cellular. BC-type matrix remains confined to the outer aspect of the GBM also in more advanced sclerotic lesions (Figure 5C), consistent with the notion that endocapillary matrix (i.e., sclerosis) is not deposited by parietal cells.

Tracing Parietal Cells in the Spontaneous Thy1.1 Mouse Model for FSGS
To trace PECs in the chronic Thy1.1 mouse model, the transgenic Thy1.1 mouse was crossed to the triple transgenic PECrtTA/LC1/R26R mouse (Figure 6A). Thy1.1 transgenic mice develop glomerular FSGS lesions as they age.21,22 Proteinuria could be observed beginning from 8 to 10 weeks after birth. Sixteen to 24 weeks after birth, about 10 to 25% of all glomeruli showed the characteristic histologic changes of segmental glomerulosclerosis of the glomerular tuft (Figure 6, B and C, arrows; normal glomeruli, arrows, arrowheads). Because the PECs were labeled by irreversible somatic recombination, the spontaneous Thy1.1 model for FSGS could be analyzed despite its long course. Aberrant genetic labeling of other glomerular cells could occur due to the spontaneous phenotype of the Thy1.1 transgene; the labeling was verified by a uninephrectomy after a washout period of the dox. The specificity of the labeling was also confirmed in Supplemental Figure 1.

Figure 4. Activated parietal cells deposit extracellular matrix. (A through D) Serial sections of four glomeruli with segmental (A through C) to global (D) sclerosis stained for the parietal cell activation marker CD44 and BC-type matrix (LKIV69). (A) Small early lesions showing expression of CD44 in a subpopulation of the PECs at the BC (arrowheads). A few CD44-positive cells bridge Bowman’s space and are attached to the glomerular tuft. The involved segment of the glomerular tuft is covered by BC type matrix which colocalizes with CD44-positive cells (A’ and A”, arrow). (B and C) More advanced lesions in which segments of the glomerular tuft are involved. CD44 is expressed by most PECs along BC (arrowheads) and also by many cells on the glomerular tuft (arrows). BC-type matrix is deposited in association with CD44-positive PECs on the glomerular tuft the BC (B” and C”, arrows). Occasionally, CD44-positive cells were seen without evidence for BC-type matrix (B, black arrow). (D) In a glomerulus with global sclerosis, CD44-positive cells (arrowheads) and BC-type matrix (arrow) are present along the entire circumference of the capillary.
that differentiated podocytes were absent from the sclerotic lesions.

Finally, it was tested whether activated PECs also participate in the formation of the matrix within sclerotic segmental lesions similar to the 5/6 Nx + DOCA-salt model. BC matrix was detected as thin deposits on the glomerular tuft of early segmental sclerotic lesions (Figure 6G, arrow). Again, BC-type matrix was always found in association with CD44-positive PECs on the glomerular tuft. In glomeruli with global sclerosis, the capillary tuft was surrounded by CD44-positive cells and contained BC-type matrix along its entire circumference (Figure 6H).

**Analysis of the Munich-Wistar-Froemter Rat Model for FSGS**

To confirm our results, a third genetic model of spontaneous FSGS was analyzed in 16-month-old Munich-Wistar-Froemter (MWF) rats. Because of an unknown genetic defect, these rats develop glomerulosclerotic lesions around the age of 16 to 20 weeks. In this model, similar results were obtained as in the above-described mouse models: Serial sections were stained consecutively for synaptopodin and CD44. Within glomeruli without evidence for sclerotic lesions, the podocyte marker synaptopodin was expressed throughout the entire capillary tuft (Figure 7A.). CD44 was not expressed in these glomeruli. However, a de novo expression of CD44 was observed in a subpopulation of single PECs (Figure 7A, black arrowhead). Within glomeruli with mild to moderate segmental sclerotic lesions, differentiated podocytes were absent within the lesions, as detected by staining for synaptopodin (Figure 7B, arrowhead). CD44 was expressed de novo within the sclerotic lesions, indicating the presence of activated PECs (Figure 7B). Similar findings were observed in advanced sclerotic lesions (Figure 7, C1, and C2). Of note, the histology of these sclerotic lesions did not show hyperplasia and therefore did not suggest the presence of additional or different cells. Nonetheless, the use of the specific markers claudin-1 (not shown) and CD44 revealed the presence of activated PECs on the affected tuft segments.

Segmental sclerotic lesions were often not detectable on all serial sections of the affected glomerulus. In these cases, CD44 expression of PECs was the only sign of a sclerotic lesion of the affected glomerulus (Figure 7D1, arrowheads). To verify that the absence of synaptopodin staining from sclerotic lesions did not occur as a result of podocyte dedifferentiation, serial sections were also stained for nestin, which has been proposed as a more stable marker for podocytes. As shown in Figure 7, E1 through E3,
nestin staining colocalized with synaptopodin staining (arrows) and was also excluded from sclerotic lesions (arrowheads). Finally, it was tested whether CD44-positive cells again colocalize with BC-type basement membrane in the MWF model. As depicted in Figure 7, F through F, BC-type matrix was deposited de novo exclusively within the segmental sclerotic lesions. There, the matrix colocalized with CD44-positive activated PECs (arrowheads; arrow with tails, autofluorescence erythrocytes). Analysis of Sclerotic Lesions in Human Renal Biopsies To test whether activated PECs are also involved in the formation of sclerotic lesions of human patients, 16 biopsies of native kidneys and 2 biopsies of transplanted kidneys were selected because they contained FSGS lesions, as diagnosed by a renal pathologist. A representative example of a patient diagnosed with primary FSGS or with hypertensive nephrosclerosis is shown in Figure 8, A through A”, and B through B”, respectively. In all sclerotic lesions, claudin-1–positive PECs were observed on the glomerular tuft. Most of the lesions coexpressed CD44 and/or BC-type matrix. As shown in Figure 8B, sclerotic lesions may easily be missed on light microscopy if specific stainings for claudin-1 or BC-type matrix are not performed. In summary, these results showed that the sclerotic lesions in our animal models recapitulated the pathomorphology of sclerotic lesions in humans.

**DISCUSSION**

In this study, we provide for the first time definite evidence that PECs participate in the formation of sclerotic lesions, which define focal and segmental glomerulosclerosis (FSGS). The sequence of events leading to glomerulosclerosis observed in three different experimental models of glomerulosclerosis is illustrated in Figure 9.

**The Pathomechanism of the Development of Sclerotic Lesions**

The process of FSGS was triggered by an initial insult of different etiologies (e.g., podocytopenia) as shown consis-
tently by others. This resulted in focal activation of PECs, which formed cellular adhesions between BC and the capillary tuft. The adhesion then provided the entry site from where PECs migrated (invaded) onto the capillary tuft. Cell lineage tracing allowed us to determine unequivocally the origin of PECs. So far, the PEC has not been recognized much—predominantly because of a lack of specific marker molecules. However, a role for PECs in the development of sclerotic lesions has been proposed before in human FSGS with mild to severe hyperplasia,\textsuperscript{25} and especially in collapsing lesions.\textsuperscript{9–14} More recently, we proposed an involvement of PECs expressing the progenitor markers CD133 and CD24 in some forms of FSGS in human biopsies.\textsuperscript{15}

In this study, the 5/6 Nx + DOCA-salt model also developed lesions with epithelial hyperplasia in a fraction of the glomeruli and we identified the proliferating cells as PECs. However, an important finding in the present study was that the histology of many glomerulosclerotic lesions in the 5/6 Nx + DOCA-salt model and especially in the models with a slower progression (i.e., chronic Thy-1.1 model and MWF model) did not suggest the presence of additional cells (i.e., activated PECs). Nonetheless, lineage tracing as well as the use of markers for PECs showed unequivocally that also in these “noncellular lesions” PECs were present on the glomerular tuft. In fact, especially in the earliest lesions the loss of podocyte markers was associated with the presence of PECs on the glomerular tuft. Therefore, the loss of podocyte markers could reflect re-
placement of podocytes by PECs rather than dysregulation or loss of markers by podocytes.

Parietal Cell Deposit Matrix
The second major finding of this study is that deposition of BC-type matrix within sclerotic lesions always colocalized with CD44 and/or claudin-1–positive PECs. The fact that in some early lesions PECs were observed without BC-type matrix deposition may suggest that the PECs invade the tuft first, and that deposition of matrix is a secondary event. The immunostainings for the two types of matrixes showed that the BC-type matrix localizes directly on the still existing GBM. This finding is also consistent with the notion that podocytes were replaced by PECs, which then synthesized new matrix on the GBM. Cai et al. have observed by immunoelectron microscopy that two different types of matrix deposition occurred in sclerotic lesions. First, they detected BC-type matrix (i.e., collagen type IV α1 and α2) on top of the GBM, which was deposited by flat epithelial cells. Because lineage tracing was not available, Cai et al. speculated at that time that these cells were “dedifferentiated podocytes”. However, our study now shows that these cells originated from PECs. Second, Cai et al. described that matrix is also deposited within the affected segment of the mesangium, which differs from the matrix deposited by activated PECs. Our study suggests that segmental mesangial sclerosis is an event secondary to the invading PECs because migrating PECs were observed also in early lesions, which had not yet developed mesangial sclerosis of the affected segment. However, no definite experimental proof for this hypothesis can be provided at this time.

Activation and Migration of PECs
The present paper demonstrates a role of PECs in the pathogenesis of FSGS lesions. According to current knowledge, these are mostly caused by podocytopenia, chronic hypertension, and hyperfiltration. The sclerotic lesions are characterized by no or mild hyperplasia of the epithelial cells. In previous studies, we and others have investigated the role of PECs in collapsing glomerulopathy (CG) and crescentic glomerulonephritis (CrGN) where the lesions are typically associated with proliferative hyperplasia within the extracapillary compartment. It was shown that PECs (and also podocytes) form the cellular or crescentic lesions within Bowman’s space. In addition, we and others observed that PECs could migrate on top of the glomerular convolute and cover or replace podocytes also in CG and CrGN. In summary, it is suggestive that the activation and migration/invasion of PECs might represent a common pathologic phenomenon in very different glomerular diseases that eventually lead to glomerular scarring.

Activated PECs Are Associated with Profibrotic Effects
The fourth major finding of this study was that activated PECs were associated with profibrotic rather than regenerative effects. This may be surprising because, in a previous study, we showed that in development a small number of (nonactivated) PECs migrate onto the glomerular tuft where they differentiate into podocytes. This has spurred the hope that this regenerative mechanism for podocytes can be used also in the adult kidney. However, in the present study, we have analyzed exclusively the fraction of glomeruli where sclerotic lesions have developed and, thus, where a possible regenerative mechanism has failed. Within these...
lesions, PECs were undoubtedly associated with profibrotic events: All sclerotic lesions contained PECs; PECs deposited matrix and were associated with mesangial sclerosis of the affected segment. No PECs were present on the remaining intact segments of the glomerular tuft outside the sclerotic lesion. These findings were also corroborated by a previous study, where we showed that PECs did not show signs of differentiation into podocytes when localized in a pathologic lesion in crescentic GN, collapsing glomerulopathy, and also some forms of FSGS.15

In this context it is also an interesting question whether additional podocyte loss may also occur secondary to invading PECs. It is clear that podocyte injury can induce the development of FSGS.6,7,28 However, in most studies, a reduced number of podocytes is associated with the presence of a glomerular scar, even if the primary injury was not directed primarily against podocytes. It is likely that podocytes can also be lost secondarily because of the invasion of PECs. In fact, as mentioned above, in previous studies we observed segmental lesions in which podocytes were directly covered by PECs.13,14,17

CONCISE METHODS

Transgenic Mice
The generation of PEC-rTαA, POD-rTαA, LC1, R26R, and Thy1.1 transgenic mice was described previously.19,21,22,29,30,31 To render the transgenic mouse lines susceptible for the development of FSGS, the mice were crossed up to five times into the 129/Sv genetic background. Animals were housed under standard SPF-free conditions. All animal procedures were approved by the LANUV NRW (8.87-50.10.35.08.106; 8.87-50.10.35.08.254 and 50.203.2 – AC 10/06).

Doxycycline Treatment
The PEC-rTαA, POD-rTαA, and PEC-rTαA/Thy-1.1 animals received doxycycline hydrochloride (dox) via the drinking water ad libitum for a total of 7 or 14 days (5% sucrose, 1 mg dox/ml, protected from light), which was exchanged every 2 days. To assure that the mice were free from dox during the experimental procedures, the mice received normal drinking water ad libitum for at least 7 days (washout period).

Animal Experiments

5/6 Nx + DOCA-Salt Model
Six-week-old PEC-rTαA and POD-rTαA mice (n = 10 each) received dox as described above. For the 5/6 Nx, the mice were anesthetized with ketamine-xylazine (100 mg/ml ketanest and 20 mg/ml xylazine in normal saline 0.9%; 0.1 ml/10 g of body wt) and after shaving a laparotomy was made. The vasculature of the right kidney was removed and used as control for the efficiency of the genetic tagging after dox treatment (t = 0). The upper and lower poles of the left kidney (two thirds of the kidney) were excised and Gelastyp (Sanofi-Aventis, Frankfurt, Germany) was used to stop

Figure 9. Schematic summary of the role of parietal cells in glomerulosclerosis. (A) A normal glomerulus consists of the endocapillary compartment (capillaries and mesangium in black) and epithelial cells: podocytes lining the capillary tuft (gray cells) and PECs lining the inside of BC (white cells). (B) Focal activation of PECs (red) and formation of an adhesion to the capillary are the first events in the formation of a sclerotic lesion. In some cases, focally activated PECs also produced more matrix on BC (pink matrix). Podocytes in the immediate vicinity of an adhesion are often effaced. (C) Activated PECs invade the affected segment of the glomerular tuft (black arrowhead) and deposit BC-type matrix. The invading PECs remain strictly within the extracapillary compartment. Occasionally, they appear disconnected from the adhesion due to tangential sections (white arrowhead). Within the endocapillary compartment, mesangial sclerosis develops within the affected segment (white arrow). Sclerosis of the glomerular tuft progresses from the adhesion. (D) Advanced sclerotic lesion. The former capillary loops are covered by parietal cells (black arrows) and BC-type matrix (pink). In advanced lesions, some invading parietal cells no longer express markers of activation (white arrows). At the site of adhesion, a continuous bridge of BC-type matrix has formed between Bowman’s capsule and the glomerular tuft (black arrowhead).
bleeding. After 7 days, a 50-mg pellet (released over 21 days) of deoxycorticosterone acetate ("DOCA"); Innovative Research, FL) was implanted subcutaneously and 0.5 to 0.9% of NaCl was added to the drinking water. During this period, body weight and proteinuria were closely monitored. New 50-mg DOCA pellets were implanted after 3 weeks and animals were sacrificed after the 6th week. The remnant left kidney was recovered and processed for histology.

**MWF Rat Model**

MWF rats are spontaneously hypertensive and develop proteinuria and FSGS. Sixteen-month-old male and female MWF rats were sacrificed and the kidneys were collected and processed for histology.

**Spontaneous ("Chronic") Murine Thy-1.1 Model**

Thy-1.1 transgenic mice ectopically express the Thy-1.1 protein on podocytes, which mediates development of proteinuria within 8 to 14 weeks after birth and FSGS lesions within the first 2 to 4 months.21,22,32,33 Four- to 5-week-old nonproteinuric quadruple transgenic PEC-rtTA/LC1/H2B-eGFP/R26R crossbreeds (n = 10) received dox for 7 days (see above) to permanently tag PECs. To verify specific labeling of PECs, a uninephrectomy (Unx, see 5/6 Nx + DOCA-salt model above) was performed after the dox washout period. Two (n = 5) and 4 (n = 5) months after the Unx, the remaining right kidney was perfused fixed and harvested for further analysis.

**Antibody Mediated ("Accelerated") Thy-1.1 Model**

Injection of anti-Thy-1.1 antibodies accelerates the development of proteinuria and FSGS in Thy-1.1 transgenic mice, resulting in an acute and massive proteinuria and dose-dependent development of collapsing FSGS lesions within 7 days.21,22,32,33 Thy-1.1, the triple transgenic PEC-rtTA reporter mouse, and the histone-2B-eGFP reporter mouse were intercrossed. The resulting mice (Thy-1.1/PEC-rtTA reporter mouse, and the histone-2B-eGFP reporter mouse) received dox for 7 days (see above) to permanently tag PECs. To verify specific labeling of PECs, a uninephrectomy (Unx, see 5/6 Nx + DOCA-salt model above) was performed after the dox washout period. Two (n = 5) and 4 (n = 5) months after the Unx, the remaining right kidney was perfused fixed and harvested for further analysis.

**Perfusion Fixation**

Mice were anesthetized (ketamine-rompun). The kidney(s) were perfused via the left heart ventricle with 3% paraformaldehyde in PBS (pH 7.6) for 3 minutes. Pieces of the kidney(s) were snap-frozen in liquid nitrogen or (post-)fixed in 3% buffered formalin and embedded in paraffin.

**Light Microscopy**

For light microscopy, the 3% buffered formalin fixed kidney fragment were dehydrated, and embedded in paraffin. Four-micrometer paraffin sections were stained with periodic acid–Schiff (PAS). To obtain the percentage of glomeruli-containing lesions, at least 60 glomeruli per mouse were evaluated for the presence of hypertrophy and hyperplasia of the glomerular epithelium, adhesions, sclerosis, or hyalnosis.

**β-Galactosidase Detection**

β-gal activity was detected using enzymatic X-gal staining as described.17 Samples were either counterstained with eosin, washed in tap water, and mounted (Immu-Mount; Thermo Scientific, Waltham, MA) or further processed for immunohistochemistry (see below).

**Immunofluorescence**

The immunofluorescence stainings were performed on 2-µm paraffin sections (for a list of primary antibodies see Table 1). The collagen IValpha3/LKIV69 and agrin/LKIV69 double stainings were performed on 2-µm acetone fixed cryosections. The following secondary antibodies were used: donkey anti-rabbit, -mouse, or -rat Dylight 488 or Dylight 549 (1:200; Dianova, Hamburg, Germany). The single-chain primary antibody (LKIV69, Table 1) was detected using anti-VSV-Cy3 (Sigma-Aldrich, St. Louis). When staining mouse sections, all secondary antibodies (except the anti-mouse antibody) were immunoadsorbed with 4% normal mouse serum. The nuclei were stained using Hoechst 33342 (Sigma-Aldrich). Sections were evaluated with an Olympus BX 41 microscope using AnalySIS software (Soft Imaging System, Muenster, Germany).

**Table 1. Primary antibodies**

<table>
<thead>
<tr>
<th>Antibody/Clone</th>
<th>Host Species</th>
<th>Reactivity</th>
<th>Dilution</th>
<th>Supplier/Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD44/IM7</td>
<td>Rat mAb</td>
<td>Mouse</td>
<td>1:200</td>
<td>BD Biosciences, San Diego</td>
</tr>
<tr>
<td>CD44/OX49</td>
<td>Mouse mAb</td>
<td>Rat</td>
<td>1:100</td>
<td>AbD Serotec, Düsseldorf, Germany</td>
</tr>
<tr>
<td>CD44/156–3C11</td>
<td>Mouse mAb</td>
<td>Human</td>
<td>1:100</td>
<td>Abcam, Cambridge, UK</td>
</tr>
<tr>
<td>Claudin</td>
<td>Rabbit pAb</td>
<td>m,r,h</td>
<td>1:50</td>
<td>Abcam, Cambridge, UK</td>
</tr>
<tr>
<td>Synaptopodin/G1D4</td>
<td>Mouse mAb</td>
<td>m,r,h</td>
<td>1:100</td>
<td>Progen, Heidelberg, Germany</td>
</tr>
<tr>
<td>Nestin</td>
<td>Chicken pAb</td>
<td>m,r,h</td>
<td>1:100</td>
<td>Abcam, Cambridge, UK</td>
</tr>
<tr>
<td>KI-67/SP6</td>
<td>Rabbit mAb</td>
<td>Mouse</td>
<td>1:300</td>
<td>Dianova, Hamburg, Germany</td>
</tr>
<tr>
<td>KI-67/MIB-1</td>
<td>Mouse mAb</td>
<td>Human</td>
<td>1:10</td>
<td>Dako, Glostrup, Denmark</td>
</tr>
<tr>
<td>GFP/JL8</td>
<td>Mouse mAb</td>
<td>Mouse</td>
<td>1:200</td>
<td>Clontech, Mountain View, CA</td>
</tr>
<tr>
<td>GFP</td>
<td>Rabbit pAb</td>
<td>Mouse</td>
<td>1:200</td>
<td>Clontech, Mountain View, CA</td>
</tr>
<tr>
<td>LKIV69</td>
<td>Single-chain Ab</td>
<td>m,r,h</td>
<td>1:50</td>
<td>Wijnhoven et al.26</td>
</tr>
<tr>
<td>Collagen IVA3</td>
<td>Mouse mAb</td>
<td>h</td>
<td>1:20</td>
<td>Wieslab AB, Ideon, Sweden</td>
</tr>
<tr>
<td>Agrin/JM72</td>
<td>Mouse mAb</td>
<td>h</td>
<td>1:200</td>
<td>Kind gift of Dr. J van der Vlag</td>
</tr>
</tbody>
</table>

m, mouse; r, rat; h, human; mAb, monoclonal antibody; pAb, polyclonal antibody.
Immunohistochemistry
Immunohistochemistry was performed on 4-μm paraffin- or 3% paraformaldehyde fixed cryo-sections. CD44, claudin-1, nestin, and synaptopodin immunostainings were combined with a PAS staining. Sections were blocked with avidin/biotin blocking kit (Vector Laboratories, Burlingame, CA) and 3% H2O2. The sections were subjected to microwave antigen retrieval in Antigen Unmasking Solution (Vector Laboratories, Burlingame, CA) followed by incubation with the primary (Table 1) and secondary antibodies. As secondary antibodies, we used biotinylated goat anti-mouse, goat anti-rabbit, goat anti-rat, and goat anti-chicken (Vector Laboratorie). Detection was carried out with vectastain ABC kit (Vector Laboratories) with the use of peroxidase as label and 3,3′-diaminobenzidine as substrate and nickel chloride enhancement. Subsequent to the immunostaining, a PAS staining was performed.

Patients
Eighteen kidney specimens were examined. Sixteen biopsies of native kidneys, and two biopsies of transplanted kidneys containing FSGS lesions, as diagnosed by a renal pathologist, were randomly selected in a blinded fashion if sclerotic lesions were observed on a PAS staining. FSGS lesions resulted from primary FSGS (n = 6), hypertensive nephrosclerosis (n = 10), or recurrent primary FSGS (n = 2). All biopsies were stained for claudin-1, synaptopodin, CD44, and BC-type extracellular matrix.

ACKNOWLEDGMENTS

This work was supported by TP17 SFB/Transregio 57 of the German Research Foundation (DFG to M.J.M.), the German Ministry for Science and Education (BMBF, 01 GN 0804 to K.E. and M.J.M.). Furthermore, this work received support from the Neph-Cure Foundation (F001 to B.S. and M.J.M.), the Genzyme Renal Innovation Program (GRIP, to B.S.), and The Netherlands Organization for Scientific Research (NWO) (2007/09196/ALW, to B.S.). M.J.M. is a member of the SFB/Transregio 57 DFG consortium “Mechanisms of organ fibrosis”. We apologize for not having cited all relevant papers due to space limitations. We thank Dr. J. van der Vlag (RUNMC, Nijmegen, The Netherlands) for providing the anti-agrin antibody.

DISCLOSURES
None.

REFERENCES


Supplemental information for this article is available online at http://www.jasn.org/.
Supplemental data

Reversible tagging of parietal cells with nuclear eGFP

In order to allow fluorescent double stainings, we sought to label specifically PECs with the nuclear fusion protein histone-eGFP (suppl. fig. 1A). For this purpose, PEC-rtTA transgenic mice were crossbred to (tet-O)\textsuperscript{7}-histone-eGFP transgenic mice\textsuperscript{1}. Upon administration of dox, the nuclei of PECs were specifically loaded with histone-eGFP, as verified by co-staining with the PEC marker claudin-1 (suppl. fig. 1B, white arrowhead). Transitional cells, located at the vascular stalk\textsuperscript{2}, were also labeled (suppl. fig. 1B, arrow). Similar to the efficiency of somatic recombination\textsuperscript{2}, about 66\% of the PECs were labeled by this method (suppl. fig. 1B,C, black arrowhead). No cell within the glomerular tuft was aberrantly labeled (suppl. fig. 1C).

CD44 is specifically expressed on PECs

To verify if CD44 is a specific marker for PECs also in a model for FSGS, the Thy1.1 transgenic mouse was crossed to the doubly transgenic PEC-rtTA/(tet-O)\textsuperscript{7}-histone-eGFP mouse (suppl. fig. 1A).

After reversible labeling of PECs with histone-eGFP, we first employed the accelerated Thy1.1 model. The accelerated Thy1.1 model has the advantage that the mice can be analyzed already 7 days after induction, so that the reversible labeling of PECs is still preserved. As depicted on suppl. fig. 1D-D’’, PECs with eGFP labeled nuclei expressed CD44 de novo. As shown on suppl. fig. 1E, a labeled PEC has migrated onto the glomerular tuft (arrow) co-expressing CD44 de novo as marker for activation. When comparing the relatively low eGFP fluorescence intensity with
other labeled PECs of the same glomerulus, it is suggestive that this activated PEC has already undergone cellular divisions.

**Legends**

**Suppl. figure 1**

**Tracking parietal cells with the reversible tag eGFP-histone in the accelerated Thy1.1 mouse model for FSGS**

A. Schematic of inducible reversible tagging of PECs in the murine Thy1.1 model. Upon administration of doxycycline (Dox), histone-eGFP is expressed within the nuclei of PECs. B. In control transgenic PEC-rtTA/(tet-O)7 histone-eGFP mice (negative for the Thy1.1 transgene), PECs (white arrowhead) as well as transitional cells (arrow) were efficiently labeled with nuclear eGFP-histone. Due to mosaic expression, not all PECs were labeled (black arrowhead). No CD44 expression was detected in these mice (not shown). C. No evidence for direct labeling of podocytes was observed when co-staining for the podocyte marker protein synaptopodin. D, E. The Thy1.1 transgene was crossed into the experimental mice (panel A). These mice developed collapsing FSGS after injection of the Thy1.1 antiserum within 8 – 14 days. D. CD44 positive FSGS lesions contained predominantly eGFP positive cells in injected triple transgenic Thy1.1/PEC-rtTA/(tet-O)7 histone-eGFP mice (white arrowheads). Significant differences in eGFP labeling intensities suggest, that a subpopulation of the PECs have undergone cellular divisions (black arrowhead), while others have not (arrow). E. A CD44 positive cells within the glomerular tuft originated from PECs, as shown by nuclear labeling with eGFP (arrow).
References


Suppl. figure 1

A. 

PEC-rtTA
parietal promoter
rtTA
+ Dox
(tet-O)_7
histone-eGFP
(tet-O)_7
histone-eGFP

Thy-1.1 mouse
mThy-1.1 promoter
mThy-1.1
3' hThy1

B.

histone-eGFP

B'.

eGFP/claudin-1/DNA

C.

histone-eGFP

C'.

synpo

C''.

merge

D.

histone-eGFP

D'.

CD44

D''.

merge

E.

histone-eGFP

E'.

CD44

E''.

merge

[Supplementary figure 1 showing immunofluorescence images of Thy-1.1 mouse parietal epithelial cells expressing histone-eGFP under the control of the parietal promoter. Images show the expression of histone-eGFP, synpo, CD44, and a merge of these markers.]